Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Prohibitin peptides are synthetic peptides derived from the coiled-coil domain (amino acids 175-217) of the tumor suppressor protein prohibitin-1 (PHB1). These peptides, which include the 42-mer H1-6, 14-mers (H1-2, H3-4, H5-6), and 7-mers (H2, H5), are designed to mimic the E2F1-binding domain of prohibitin. By mimicking this domain, the peptides repress E2F1-mediated transcription, recruit histone deacetylase 1 (HDAC1), and arrest cell proliferation. Preclinical studies demonstrate that prohibitin peptides induce apoptosis in breast, lung, and prostate cancer cell lines, reduce the invasive capability of cancer cells, and inhibit angiogenesis in endothelial cells, while sparing normal epithelial cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on prohibitin peptides.